Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia

作者
N. А. Avxentyev,M. Yu. Frolov,A. Makarov
出处
期刊:PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology [Irbis (Czechia)]
卷期号:11 (2): 27-37 被引量:1
标识
DOI:10.17749/2070-4909.2018.11.2.027-037
摘要

Ilmatinib is currently the most widely used tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia (CML) in Russia. When patients develop resistance or intolerance to imatinib, second generation tyrosine kinase inhibitors (Tkis) are used. in Russia, nilotinib, dasatinib and bosutinib are registered in second-line, however only dasatinib is included in the government drug reimbursement program. The aim of this study was to conduct a pharmacoeconomic comparison of nilotinib, dasatinib and bosutinib as second-line treatments for patients with CML from the Russian healthcare system perspective. Materials and methods. Using the clinical trial data we developed a Markov model of CML progression on nilotinib, dasatinib or bosutinib second-line therapy and calculated the medical costs per patient. Both costeffectiveness analysis and budget-impact analysis reflected the local practice and the drug reimbursement approval process. Results. The average medical cost (per year) for nilotinib (1 683 thousand rubles or US$27 075) was 8.4% lower than that for dasatinib and 35.2% lower than for bosutinib. The 4-year total medical cost of treatment with nilotinib was 4 372 thousand rubles (US$ 70 336), which was 13.9% lower compared to dasatinib and 37.3% lower compared to bosutinib. nilotinib also had a lower cost/effectiveness ratio (US$ 1 602, 1 910 and 2 537 per life month for nilotinib, dasatinib and bosutinib, respectively). The estimated number of patients in Russia who need second-line treatment for CML is 996 patients. if nilotinib were included in the Government Reimbursement Program, a saving of 771 million rubles (US$ 12,4 million) over four years would be reached. Conclusions. When compared with dasatinib or bosutinib, nilotinib is the cost-saving option for the second-line treatment of CML patients in Russia.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
Lny发布了新的文献求助10
1秒前
金山时雨完成签到,获得积分10
2秒前
2秒前
2秒前
Nole的应助被哈哈哈采纳,获得10
2秒前
3秒前
羊咩咩发布了新的文献求助20
4秒前
4秒前
hai完成签到,获得积分10
5秒前
5秒前
无极微光的应助被保持客气采纳,获得30
5秒前
核桃发布了新的文献求助10
5秒前
水天需发布了新的文献求助30
5秒前
5秒前
zoe完成签到 ,获得积分10
6秒前
阔达幼珊完成签到,获得积分10
7秒前
眼睛大的可乐完成签到,获得积分10
7秒前
can发布了新的文献求助10
7秒前
hai发布了新的文献求助10
8秒前
8秒前
9秒前
9秒前
10秒前
独角戏完成签到,获得积分10
10秒前
WWT发布了新的文献求助10
10秒前
10秒前
端庄问蕊发布了新的文献求助10
11秒前
John的应助被冷傲的不愁采纳,获得10
12秒前
12秒前
正直道消发布了新的文献求助10
12秒前
vitrimer发布了新的文献求助10
12秒前
北林完成签到,获得积分10
12秒前
13秒前
埋头赶路完成签到,获得积分10
13秒前
1122发布了新的文献求助10
13秒前
13秒前
今后的应助被mate采纳,获得10
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183894
求助须知:如何正确求助?哪些是违规求助? 9573067
关于积分的说明 21829226
捐赠科研通 7780983
什么是DOI,文献DOI怎么找? 3434150
关于科研通互助平台的介绍 2558315
邀请新用户注册赠送积分活动 2480648